TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Absolute Change in Percent Predicted FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain at 24 hours postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in UPDRS III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of contact attempts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of micturitions in a 24 hour bladder diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of urge urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of hearing-impaired infants with abnormal vestibular screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volatile organic compounds in exhaled breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wellness Program participation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Nighttime Total Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Occurrence of safety events related to DEX administration
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral health treatment initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: disease free survival after 2 and 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity-Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity-MVPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Extremity Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form-12 Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Final diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Frequency of Vasomotor Symptoms at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Average Daily Severity of Moderate/Severe Vasomotor Symptoms at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ACQ Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving a decrease in serum iPTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Self-reported attempts to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Microvascular invasion of the tumor capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Treatment-Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Best response using the World Health Organization response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose defined as the highest safely tolerated dose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: circulating TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of MF101
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Pain (Total Opioid Use)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laser-on time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lymph node metastasis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Discrimination of tissue types
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the size of oral erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the depth of oral erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the degree of erythema of oral erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: glycemic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modulation of HIF-1 alpha mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Conversion to psychosis
Endpoint domain: Adverse events/effects
Primary endpoint: Left ventricular end-systolic volume (LVSV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ASAS 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASAS 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured Limbal Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine equivalent use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RCB Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quick Drink Screen (QDS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PTSD Checklist-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measured Glomerular Filtration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Unintentional medication discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Technical features evaluation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in state trait anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absolute Change in Lung Clearance Index 2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to diagnosis of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from administration to last observed concentration (AUC (0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration half-life (t ½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of manual fluid-distension methods
Endpoint domain: Adverse events/effects
Primary endpoint: Technical success of endoscopic pylorotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants Providing Biologic Samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serologically confirmed HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: Percent reduction from baseline in seizure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percent reduction in drop attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Parent/guardian global evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Cortical Inhibition (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG-EMG coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC QLQ-C30 Functional scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EORTC QLQ-C30 Symptom scales
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: EORTC QLQ-CR29 Functional scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EORTC QLQ-CR29 Symptom scales
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Mean Monthly Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Mean Monthly Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Who Experienced an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Doses (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: total volume of the seroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroma punctures
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants Achieving Clinical Remission at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Achieving Endoscopic Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total NOSE score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of renal cortical tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in knowledge regarding a healthy diet and nutrition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurological Assessment for Motor Function and Reflexes/Sensory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment Emergent Adverse Events- Relationship to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSH level 6 months after end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of joint angle measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of antibiotic resistant organisms
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of high risk for developing diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treatment related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of skin lesions and healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Level of cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective evaluation of physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective evaluation of physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Clinically significant changes in safety laboratory tests, physical examinations, vital signs, or ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of anti-AMG 167 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumour control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Not Eligible for Antiviral Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Evaluation Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdose QTcF intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower limbs Motor function: ASIA motor score (LEMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Colonic Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in number of bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in defecation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Somatic and psychoemotional premenstrual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of Risperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from Hour 0 to the last measurable concentration (AUC0 t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Improvement scale (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peripheral venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of FLT3, NPM1 and CEBPa mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fracture Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peak walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cough VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in laryngeal histamine threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cough histamine threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose incremental area under the blood glucose response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to First Cardiovascular Events Adjudicated Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Reporting a Cardiovascular Events Adjudicated Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postconcussive sensory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of NIHSS at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of common mental disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working Alliance Inventory Sum Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Client Satisfaction Sum Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prescription of insulin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pressure pain threshold change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour systolic ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fractional synthetic rate of muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Jankovic Rating Scale (JRS) Severity Subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of fully retractile foreskin with full exposure of glans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Vertical Alveolar ridge height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning Peak Expiratory Flow (mPEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and treatment related deaths at 3 months after study completion
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity assessed by NCI criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of clinical infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean change in plasma glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fever and infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of digital exams
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of new actinic keratoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: numbers and percentages of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional tests of postural control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 16D health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in PedsQL health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physician's Global Assessment Scale for Improvement of Spider Angioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Quality of Color Vision Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Reporting More Positive Than Negative Comments About the Use of the EnChroma Glasses
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Competence of individual clinicians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice of individual clinicians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in Gingival bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Rapamycin (Sirolimus)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically applicable intra-operatively acquired fMRI data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with spatially accurate co-registered pre-operative DTI data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in language fMRI data for participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of vascular patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Wang clinical severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion who have the TR-band removed within 90,120 and 180 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of falls
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total physical activity time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: OTA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAScog/11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FeNO measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pain severity/score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of Sobriety in First 90 Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days of Use in Prior 30 Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weeks of Sobriety
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intensity of pain after cesarean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ThermoDox in combination with Hyperthermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: salivary amylase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procalcitonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes